The first 60 days: KIT exon 11-mutant GIST
Most GISTs are driven by a mutation in exon 11 of the KIT gene, which keeps the KIT growth receptor switched on. Imatinib blocks it: given for three years after surgery in higher-risk tumours it prevents relapse and extends life, and in metastatic disease it controls the tumour for years before resistance develops. Below, week by week, is what OnCo's record of KIT exon 11-mutant GIST says about the first two months: the order is typical, the timing is yours to ask about. Sections appear only where the record has something to say. Orientation, not medical advice.
What happens now
Staging tests establish exactly what and where the cancer is. Everything else follows from the answers.
Ask which of these were tested and what the results were; see the report reader for what each value means.
These specialties appear in the standard of care for this cancer. In most centres they meet weekly as a tumour board to agree each plan; you can ask when yours was discussed and what was decided.
- PathologistNamed in the standard of care for: Progression on imatinib.
- RadiologistNamed in the standard of care for: Metastatic, first line.
- SurgeonNamed in the standard of care for: Localised, resectable.
- Medical oncologistNamed in the standard of care for: Localised, resectable, After resection, high risk, Metastatic, first line, Progression on imatinib.
A second opinion from a centre that treats many similar cases is normal, not rude; the standard of care tells you what to compare it against.
Each row is a setting from the standard of care, in the order it usually arises. Not all will apply to you; your stage and biomarkers decide which do. The guideline grade, where recorded, says how strong the evidence is.
Complete surgical resection without lymphadenectomy; laparoscopic for smaller gastric tumours; neoadjuvant imatinib for large or poorly placed tumours.
Three years of adjuvant imatinib 400 mg (SSG XVIII); trials of longer courses.
Imatinib 400 mg continued until progression, with CT response assessment by Choi criteria.
Dose escalation to 800 mg, then sunitinib, regorafenib and ripretinib, ideally guided by the secondary mutation on circulating tumour DNA.
Generated from this cancer's standard of care, biomarkers and open problems. Take the group that matches where you are. To tick, add your own and print, open the one-page appointment sheet.
Newly diagnosed
- What is my exact diagnosis, stage, and grade, and which tests established them?Everything else follows from an accurate stage and subtype.
- Which biomarkers have been tested on my tumour (for example KIT exon 11 mutation type, Mitotic count, size and site, KITand DOG1 immunohistochemistry, Secondary KIT mutations on progression, Imatinib plasma level in poor responders), and what were the results?These results decide eligibility for targeted therapy, immunotherapy, and trials.
- Which subtype is my cancer, and does that change the recommended treatment?Recognised subtypes for this cancer include KIT exon 11 deletion, KIT exon 11 substitution or duplication, Localised KIT exon 11-mutant GIST, high risk.
- Is germline (inherited) genetic testing recommended for me or my family?Inherited variants can change treatment and matter for relatives.
Localised, resectable
- For my situation (localised, resectable), which of the standard options do you recommend and why?Guideline options include: Complete surgical resection without lymphadenectomy; laparoscopic for smaller gastric tumours; neoadjuvant imatinib for large or poorly placed tumours.
- Am I a candidate for Imatinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
After resection, high risk
- For my situation (after resection, high risk), which of the standard options do you recommend and why?Guideline options include: Three years of adjuvant imatinib 400 mg (SSG XVIII); trials of longer courses.
- Am I a candidate for Imatinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Metastatic, first line
- For my situation (metastatic, first line), which of the standard options do you recommend and why?Guideline options include: Imatinib 400 mg continued until progression, with CT response assessment by Choi criteria.
- Am I a candidate for Imatinib, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Progression on imatinib
- For my situation (progression on imatinib), which of the standard options do you recommend and why?Guideline options include: Dose escalation to 800 mg, then sunitinib, regorafenib and ripretinib, ideally guided by the secondary mutation on circulating tumour DNA.
- Am I a candidate for Imatinib, Sunitinib, Regorafenib or related drugs, and what side effects should I expect?Knowing the expected toxicities helps you plan work, family, and supportive care.
Any stage
- Are there clinical trials I could join, for example of IDRX-42, NB003, Bezuclastinib, Liquid biopsy (ctDNA)?Trials are how the next standard of care is set; asking early keeps options open.
- Would a second opinion at a high-volume centre change anything, and can you help arrange it?Rare or high-stakes decisions benefit from a centre that treats many similar patients.
- What supportive care (symptom control, nutrition, exercise, mental health, financial help) is available from the start?Supportive care improves quality of life and helps patients complete treatment.
- I read that “Whether adjuvant imatinib should continue for five years or longer”. How does that affect my plan?Open problems are where trials and second opinions matter most.
- I read that “Resistance through secondary KIT mutations in nearly every metastatic patient”. How does that affect my plan?Open problems are where trials and second opinions matter most.
Trials open now for this cancer in OnCo, largest phase first. Joining a trial is a decision like any other: ask what the comparison arm is, whether a placebo is used, and what happens if you leave. The cancer page searches ClinicalTrials.gov live for more.
Much of what helps in the first weeks is free if you know to ask: testing, helplines, rides and lodging, second opinions, trial travel.
- KIT exon 11-mutant GIST: the full pageMost GISTs are driven by a mutation in exon 11 of the KIT gene, which keeps the KIT growth receptor switched on. Imatinib blocks it: given for three years after surgery in higher-risk tumours it prevents relapse and extends life, and in metastatic disease it controls the tumour for years before resistance develops.
- One-page appointment sheetYour questions, the words you may hear, what to bring, and space for the answers. Print it.
- Treatment sequencingWhich treatment tends to follow which, line by line.
- NavigatorStandard of care for your stage, what you have tried, and trials near you.
- Circulating tumour DNA (ctDNA): Circulating tumour DNA (ctDNA) consists of fragments of DNA shed by tumour cells into the blood, detectable with sensitive sequencing.
Every term links to the glossary.